Captrust Financial Advisors Has $4.88 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Captrust Financial Advisors lifted its stake in Boston Scientific Co. (NYSE:BSX) by 18.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 54,580 shares of the medical equipment provider’s stock after purchasing an additional 8,316 shares during the period. Captrust Financial Advisors’ holdings in Boston Scientific were worth $4,875,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. TFC Financial Management Inc. boosted its position in shares of Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 210 shares in the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth about $29,000. Valley National Advisers Inc. raised its position in shares of Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 286 shares during the period. Fairway Wealth LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at about $36,000. Finally, Global Trust Asset Management LLC grew its position in shares of Boston Scientific by 64.5% in the 4th quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 171 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of research reports. Stifel Nicolaus lifted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. BTIG Research reiterated a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a report on Wednesday, April 23rd. Truist Financial boosted their price target on Boston Scientific from $113.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, April 24th. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, April 29th. Finally, Robert W. Baird upped their price target on Boston Scientific from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, April 24th. Twenty-three investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $114.52.

Boston Scientific Stock Down 0.4 %

Boston Scientific stock opened at $102.87 on Friday. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The stock has a market cap of $152.19 billion, a P/E ratio of 82.30, a P/E/G ratio of 2.79 and a beta of 0.68. The company’s 50-day moving average price is $98.68 and its two-hundred day moving average price is $95.93. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the previous year, the company posted $0.56 EPS. The firm’s quarterly revenue was up 20.9% on a year-over-year basis. As a group, analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 4,572 shares of the firm’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the transaction, the executive vice president now owns 18,705 shares in the company, valued at approximately $1,955,420.70. This trade represents a 19.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig sold 12,000 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the sale, the director now directly owns 24,398 shares of the company’s stock, valued at $2,573,501.04. This represents a 32.97 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 300,497 shares of company stock valued at $31,056,815. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.